Sun genomics has announced that the company has successfully secured the $8.65 Series A Funding. The company has further added that the funding round was led by Nascita Ventures, Human Longevity, SOSV, Pangaea Ventures and Danone Manifesto Ventures.
The company is the first company to market the completely personalized probiotic solutions based on sequential diagnostics.
Founder and Chief Executive Officer of Sun Genomics, Sunny Jain said, “As we continue to understand the connection between the microbes in our gut and immune system dysfunction, consumers are becoming increasingly interested in their own personal microbiome, seeking solutions to gut-related issues.”
“We are building the world’s largest longitudinal dataset to better understand gut health, allowing us to custom design probiotics for the exact needs of each and every customer. Today’s announcement is a clear indicator in the progress we have made and our future potential. We are excited to work with our new partners to reach even more consumers,” Sunny Jain further added in the statement.
General Partner and Founder of Pangaea Ventures, Chris Erickson said, “Sun Genomics is a market leader in microbiome analysis and gut health.”
“We value the impact they make on physical health, immunity, and mental health with many more clinically relevant opportunities to come. We are excited to be an investor and look forward to working with the Sun Genomics team to build a world-class company,” Chris Erickson further added in the statement.
Chief Executive Officer of Danone Manifesto Ventures, Laurent Marcel said, “We see Sun Genomics as a leader in bringing personalized probiotics to consumers, blending scientific knowledge of the microbiome with new ways of providing customized health solutions.”
“Backed by Danone’s strong scientific expertise in gut, immunity and microbiome, we are excited to support Sun Genomics into their next stage of growth,” Laurent Marcel further added in the statement.